ArticleScience advances2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 2 pooled it
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 2 syntheses or guidelines pooled it, 302 citations in OpenAlex.
- ATM is associated with the prognosis of colorectal cancer: a systematic review.Frontiers in oncology · 2025Pooled it
- Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.Frontiers in oncology · 2022Pooled it
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies.iScience · 2026Article
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma.International journal of radiation oncology, biology, physics · 2026Review
- Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.Neuro-oncology · 2026Review
- DNA-PKcs inhibition sensitizes glioblastoma to radiotherapy through reprogramming of tumor cell states and immune microenvironment cell types.Research square · 2026Article
- ATM inhibition restores IFN-γ sensitivity and induces ferroptosis in NSCLC via DNA damage response.Biochemistry and biophysics reports · 2026Article
- XPF mediates 3' flap processing for FEN1-independent Okazaki fragment maturation.Nucleic acids research · 2026Article
- The double-edged sword of tumor-targeted treatment: the influence of targeted therapy on the heart.Translational cancer research · 2026Review
- Inhibition of ATM reverses radioiodine resistance in differentiated thyroid cancer via genotoxic stress amplification.Journal of translational medicine · 2026Article
- Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability.Cancer gene therapy · 2026Article
- O-GlcNAcylation of NONO mediates alternative splicing of SETMAR and facilitates NHEJ repair.Genome biology · 2026Article
- Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses.bioRxiv : the preprint server for biology · 2026Article
- Innate immunity in tumour immunoediting and immunosurveillance.The EMBO journal · 2026Review
- Tumor suppressor network dysregulation in neuroblastoma: molecular mechanisms and precision therapeutic opportunities.Frontiers in cell and developmental biology · 2026Review
- Inhibition of ATM, ATR and DNA-PK radiosensitises 3D uveal melanoma models to X-rays and proton beam therapy.Frontiers in oncology · 2026Article
- Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy.World journal of surgical oncology · 2025Review
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 6 institutions in 5 countries.
Stephen T DurantBioscience, Oncology Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0003-4209-7499
Li ZhengBioscience, Innovative Cancer Centre, Oncology IMED Biotech Unit, AstraZeneca, Shanghai, China.ORCID 0000-0003-0036-1271
Yingchun WangBioscience, Innovative Cancer Centre, Oncology IMED Biotech Unit, AstraZeneca, Shanghai, China.
Kan ChenDrug Metabolism and Pharmacokinetics, Innovative Cancer Centre, Oncology IMED Biotech Unit, AstraZeneca, Shanghai, China.
Lingli ZhangDrug Metabolism and Pharmacokinetics, Innovative Cancer Centre, Oncology IMED Biotech Unit, AstraZeneca, Shanghai, China.
Tianwei ZhangBioscience, Innovative Cancer Centre, Oncology IMED Biotech Unit, AstraZeneca, Shanghai, China.
Zhenfan YangBioscience, Innovative Cancer Centre, Oncology IMED Biotech Unit, AstraZeneca, Shanghai, China.
Lucy RichesBioscience, Oncology Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca, Cambridge, UK.
Antonio G TrinidadBioscience, Oncology Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca, Cambridge, UK.
Jacqueline H L FokBioscience, Oncology Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0002-6563-3023
Tom HuntChemistry, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0003-1227-8862
Kurt G PikeChemistry, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Joanne WilsonDrug Metabolism and Pharmacokinetics, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Aaron SmithDrug Metabolism and Pharmacokinetics, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Nicola ColcloughDrug Metabolism and Pharmacokinetics, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Venkatesh Pilla ReddyDrug Metabolism and Pharmacokinetics, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0002-7786-4371
Andrew SykesDrug Metabolism and Pharmacokinetics, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0003-2257-4841
Annika JanefeldtDrug Metabolism and Pharmacokinetics, Cardiovascular and Metabolic Diseases IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-9378-4064
Peter JohnströmPrecision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
Katarina VarnäsDepartment of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Akihiro TakanoDepartment of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Stephanie LingDiscovery Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Jonathan OrmeDiscovery Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Jonathan StottDiscovery Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Caroline RobertsDiscovery Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0001-7846-9800
Ian BarrettDiscovery Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Gemma JonesTranslational Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Martine RoudierTranslational Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0002-2862-7636
Andrew PierceTranslational Sciences, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0002-0738-2756
Jasmine AllenDepartment of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0058, USA.
Jenna KahnDepartment of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0058, USA.
Amrita SuleDepartment of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0058, USA.
Jeremy KarlinDepartment of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0058, USA.ORCID 0000-0003-4322-1041
Anna CroninDrug Safety and Metabolism, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Melissa ChapmanDrug Safety and Metabolism, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Kristoffer ValerieDepartment of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0058, USA.ORCID 0000-0002-7907-7873
Ruth IllingworthOperations, AstraZeneca, Waltham, MA 02451, USA.
Martin PassProjects, Oncology IMED Biotech Unit, AstraZeneca, Cambridge, UK.
AstraZeneca (United Kingdom) · GBAstraZeneca (Japan) · JPVirginia Commonwealth University · USAstraZeneca (United States) · USStockholm County Council · SEAstraZeneca (South Korea) · KR
Funding
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0MATM as target for malignant glioma radiosensitization.R01NS064593 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI VALERIE, KRISTOFFER CARL · 2009 to 2013
$1.7MNovel, orally available ATM inhibitor for glioma conformal radiosensitizationR21CA194789 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI VALERIE, KRISTOFFER CARL · 2016 to 2017
$365kGAMMACELL 40 137 CS IRRADIATORS10RR022443 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI VALERIE, KRISTOFFER CARL · 2006 to 2006
$361kTargeting invasion and DNA DSB repair in glioma with a multi-pronged approach.R21CA156995 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI VALERIE, KRISTOFFER CARL · 2011 to 2012
$358kNCI NIH HHS P30 CA016059NCI NIH HHS R21 CA156995NCI NIH HHS R21 CA194789NCRR NIH HHS S10 RR022443NINDS NIH HHS R01 NS064593
Abstract
Poor survival rates of patients with tumors arising from or disseminating into the brain are attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain barrier (BBB) penetration of chemotherapies/targeted agents, and an intrinsic tumor radio-/chemo-resistance. Ataxia-telangiectasia mutated (ATM) protein orchestrates the cellular DNA damage response (DDR) to cytotoxic DNA double-strand breaks induced by ionizing radiation (IR). ATM genetic ablation or pharmacological inhibition results in tumor cell hypersensitivity to IR. We report the primary pharmacology of the clinical-grade, exquisitely potent (cell IC
Indexed as
AnimalsApoptosisAtaxia Telangiectasia Mutated ProteinsBlood-Brain BarrierBrain NeoplasmsCell Line, TumorCell Membrane PermeabilityDisease Models, AnimalDrug Evaluation, PreclinicalHumansMicePhosphorylationProtein Kinase InhibitorsRadiation-Sensitizing AgentsRadiation ToleranceSignal TransductionAtaxia Telangiectasia Mutated ProteinsProtein Kinase InhibitorsRadiation-Sensitizing AgentsTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.